De tre små produktene som er på vei til BP for å gjøre seg fete
Det var en gang tre små produkter, Vac , Nac og Chem som skulle til BF for å gjøre seg fete .... Slik begynner jo eventyret ....Der kan de bli sikkelig fete slik at aksjonærene i pcib kan feire jul og ikke gå i fella, men passe seg for den...
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
teaa
13.11.2020 kl 14:14
2585
AstraZeneca har smakt på fimaNAC i fem år, men likevel ikke gjort PCIB fete.
De takket nei til videre satsning på dette produktet.
Det kan være langt fra interessante og lovende resultater til store inntekter....
Men vi kan jo håpe at andre finner det interessant å kjøpe teknologien?
De takket nei til videre satsning på dette produktet.
Det kan være langt fra interessante og lovende resultater til store inntekter....
Men vi kan jo håpe at andre finner det interessant å kjøpe teknologien?
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
sokaratest
13.11.2020 kl 16:02
2508
Det gjelder å ikke se troll på lyse dagen ... AZ og Pcib vil ganske snart publisere data og funn som er oppsiktsvekkende
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
Nissen (merida1) er med på lasset . En riktig God Førjulstid til alle medaksjonærer!
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
Christkr
13.11.2020 kl 20:35
2296
Om det hadde vært noe å fete seg på her, så hadde BP sirklet rundt som gribber. Men menigheten har kanskje forstått noe som ingen andre har.....
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
sokaratest
14.11.2020 kl 13:34
2102
Slettet brukerskrev Nissen (merida1) er med på lasset . En riktig God Førjulstid til alle medaksjonærer!
Kanskje lyset kommer til advent
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
bravi
14.11.2020 kl 16:13
2009
Slettet brukerskrev Nissen (merida1) er med på lasset . En riktig God Førjulstid til alle medaksjonærer!
Det er flere nisser med på lasset, bla. emisjonsfantomet Einarsson, han med podcastene.
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
Kanskje ikke dumt å henge seg på et suckers rally
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
fabian2
15.11.2020 kl 16:51
1664
Ja , du merida , du merida , du får vel følge med i morgen , noen oppfattet meldingen fra USA like før norsk børs stengetid fredag.
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
sokaratest
15.11.2020 kl 17:01
1627
Veldig spennende !
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
sokaratest
15.11.2020 kl 17:02
1627
Veldig spennende !
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
Melding? Oppdatering
Det være seg lurt å henge seg på en stund, skriver jeg . Liker du ikke formuleringen min. fabian 2 ?
Det være seg lurt å henge seg på en stund, skriver jeg . Liker du ikke formuleringen min. fabian 2 ?
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare
teaa
23.11.2020 kl 09:01
1070
23.11.2020, 08:30 · GlobeNewswire
PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the fimaVacc technology is accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is "Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers” and the abstract of the publication is available through this link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/abstract.
The open label Phase I study in more than 90 healthy volunteers was completed in 2019 and conducted to assess the safety, tolerability and immune response to fimaVacc with intradermal vaccination. The overall results provide proof-of-concept by demonstrating that fimaVacc enhances the immune responses to peptide and protein based vaccines in healthy volunteers. The results further support fimaVacc’s potential to enhance the cellular immune responses that are especially important for therapeutic effect of vaccines. Moreover, the study shows that fimaVacc can be safely employed in humans.
Per Walday, CEO of PCI Biotech, comments: We are delighted to publish the fimaVacc Phase I data in a high-impact immunology journal. The results of this study showed that employment of fimaVacc provided a substantial increase in the number of subjects exhibiting a T-cell response to an HPV peptide based vaccine. An improved CD8+ T-cell response was also seen with fimaVacc, which is a highly sought-after feature of therapeutic vaccination technologies. We now look forward to disseminating these results and move the fimaVacc technology into a disease setting.
The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fimaVacc in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). The results show a substantial increase in number of T-cell responders to HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The employment of fimaVacc increased the number of subjects exhibiting a T-cell response to the HPV peptide vaccine about 10-fold over what was achieved with the vaccine and adjuvant (Hiltonol) combination without fimaVacc. Moreover, the use of fimaVacc seemed to result in a more consistent and multifunctional CD8+ T-cell response.
The study was performed in collaboration with international experts, including staff at the Department of Medical Oncology at Leiden University Medical Centre (LUMC) under the leadership of Professor Sjoerd van der Burg. The Phase I study and the general development of the fimaVacc technology is supported by a grant from the Research Council of Norway (Forskningsrådet).
Contact information:
Per Walday, CEO
PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the fimaVacc technology is accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is "Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers” and the abstract of the publication is available through this link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/abstract.
The open label Phase I study in more than 90 healthy volunteers was completed in 2019 and conducted to assess the safety, tolerability and immune response to fimaVacc with intradermal vaccination. The overall results provide proof-of-concept by demonstrating that fimaVacc enhances the immune responses to peptide and protein based vaccines in healthy volunteers. The results further support fimaVacc’s potential to enhance the cellular immune responses that are especially important for therapeutic effect of vaccines. Moreover, the study shows that fimaVacc can be safely employed in humans.
Per Walday, CEO of PCI Biotech, comments: We are delighted to publish the fimaVacc Phase I data in a high-impact immunology journal. The results of this study showed that employment of fimaVacc provided a substantial increase in the number of subjects exhibiting a T-cell response to an HPV peptide based vaccine. An improved CD8+ T-cell response was also seen with fimaVacc, which is a highly sought-after feature of therapeutic vaccination technologies. We now look forward to disseminating these results and move the fimaVacc technology into a disease setting.
The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fimaVacc in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). The results show a substantial increase in number of T-cell responders to HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The employment of fimaVacc increased the number of subjects exhibiting a T-cell response to the HPV peptide vaccine about 10-fold over what was achieved with the vaccine and adjuvant (Hiltonol) combination without fimaVacc. Moreover, the use of fimaVacc seemed to result in a more consistent and multifunctional CD8+ T-cell response.
The study was performed in collaboration with international experts, including staff at the Department of Medical Oncology at Leiden University Medical Centre (LUMC) under the leadership of Professor Sjoerd van der Burg. The Phase I study and the general development of the fimaVacc technology is supported by a grant from the Research Council of Norway (Forskningsrådet).
Contact information:
Per Walday, CEO
Redigert 21.01.2021 kl 08:47
Du må logge inn for å svare